amorchem header logo close button Menu
arrow leftBack to portfolio

SL2

The SL2 project, focused on the work of Dr. Sidong Huang and his collaborator, Dr. Martin Schmeing, from the Rosalind and Morris Goodman Cancer Research Centre, will focus on the identification of small molecules to treat small cell carcinoma of the ovary, hypercalcemic type (“SCCOHT”).

SCCOHT is an aggressive, rare form of ovarian cancer which affects predominantly women in their 20s. With 65% of patients dying within two years, this severe disease represents a definite unmet medical need. If the usefulness of targeting SL2 with small molecules can be proven in SCCOHT, we believe it will also be possible to extend the use of its inhibitors to other oncology indications, such as non-small cell lung cancer.